Long-term antibody response following SPUTNIK V primary vaccination in healthcare workers with and without history of SARS-CoV-2 infection: Prospective cohort study from a hospital in Argentina. (August 2022)

• Record Type: Journal Article
• Authors: Gentile, A.; Castellano, V.E.; Pacchiotti, A.; Weinberger, N.; Diana Menéndez, S.; del Pino, M.; Carciofi, G.; Lamy, P.; Mistchenko, A.S.
• Is Part Of: Vaccine. Volume 11(2022)
• Publication Date: 2022-08
• Subjects: COVID-19 -- Sputnik V vaccine -- Antibodies -- Health-care workers
• DOI: 10.1016/j.jvacx.2022.100187
• Languages: English
• ISSNs: 2590-1362

Abstract

Highlights: After completing a two-dose Sputnik V schedule, all vaccinees developed antibodies. Prior infection was associated with higher antibody concentrations. Antibodies decreased significantly after 6 months in naïve subjects. In subjects without infection, 17% were negative at day 180. SARS-CoV2 infection after vaccination increased antibody concentrations. Abstract: Background: In December 2020, Sputnik V was incorporated to the National COVID-19 Immunization Plan in Argentina. Studies had shown 98% of antibody response rate. To date, data on immunogenicity and antibody persistence in Argentina are scarce. The objective was to assess humoral immune response after two doses of Sputnik V in Health Care Workers (HCWs) at the Ricardo Gutierrez Children's Hospital (RGCH). Methods: A prospective, cohort study in HCWs immunized with two doses of Sputnik V between February and March 2021. The following variables were assessed: age, gender, risk factors for severe COVID-19 or mortality, immunosuppressive therapy and history of SARS-CoV-2. Blood samples were drawn on the day of the first dose, 28 days and 180 days after the second. Anti-Spike IgG was measured using an ELISA assay. Differences in immune response were evaluated according to study variables. Comparison analyses between groups with or without history of infection were performed, with T-test and ANOVA or Mann-Whitney tests. For each subject, we compared baseline values with 28 days and 180 days after the second vaccine. STATA version 14 and R Sofware were used for data analyses. Results: We included 528 individuals, mean age 41.5 years, 82.9% female, 14.4% (76/528) reported previous SARS-CoV-2 infection. All subjects developed antibodies post-vaccination. At day 28, concentrations were significantly higher in previously infected than naïve subjects (p < 0.001) with no differences according to age, gender and comorbidities. At day 180, 17% (95% CI 13.17–21.53) of naïve subjects were negative. Antibody concentrations decreased significantly in all subjects except in those who reported SARS-CoV-2 infection after vaccination (n = 31). This last group had significantly higher antibody concentrations. Conclusion: This study assessed immune response to a new COVID-19 vaccine in real life in a cohort of subjects. Antibody concentrations varied according to history of SARS-COV-2 infection and decreased over time.